The data that we gathered from a protein-protein interaction (PPI) prediction tool, FpClass, and a limited number of studies indicated that the chaperones HSP90AA1, HSPA4, STUB1/CHIP might interact with amyloid-β (Aβ) and/or tau and could subsequently be co-released into the cerebrospinal fluid (CSF). Therefore, we investigated CSF levels of HSP90AA1, HSPA4, and STUB1/CHIP in Alzheimer's disease (AD), Non-AD mild cognitive impairment (Non-AD MCI), and frontotemporal dementia (FTD) cases.
Methods
The CSF levels of HSP90AA1, HSPA4, STUB/CHIP, and core AD biomarkers were determined by ELISA in AD (n = 90), Non-AD MCI (n = 27), FTD (n = 15), and subjective cognitive impairment (SCI) (n = 20) subjects.
Results
HSP90AA1 levels were significantly higher in AD cases compared to the SCI subjects. The CSF levels of STUB1/CHIP were significantly lower in AD, Non-AD MCI and FTD cases compared to the SCI subjects. STUB1/CHIP levels of FTD cases were significantly lower than all other groups. HSPA4 levels was correlated with core AD biomarkers (Aβ 1–42, p-Tau, t-Tau) regardless of disease. Non-APOE ε4 carrier FTD cases also had significantly lower STUB1/CHIP levels than other groups.
Conclusions
The STUB1/CHIP holds promise as a potential biomarker for distinguishing between SCI subjects, AD, and FTD. Furthermore, APOE might serve as an additional discriminatory factor that might be integrated with this chaperone for enhanced discrimination.
Addressing global dementia. Lancet2014; 383: 2185.
2.
PapadimitriouCCelikkayaHCosacakMI, et al.3D Culture method for Alzheimer's disease modeling reveals ınterleukin-4 rescues Abeta42-ınduced loss of human neural stem cell plasticity. Dev Cell2018; 46: 85–101.e8.
3.
AtasoyILDursunEGezen-AkD, et al.Both secreted and the cellular levels of BDNF attenuated due to tau hyperphosphorylation in primary cultures of cortical neurons. J Chem Neuroanat2017; 80: 19–26.
4.
Gezen-AkDAlayliogluMYurttasZ, et al.Vitamin D receptor regulates transcription of mitochondrial DNA and directly interacts with mitochondrial DNA and TFAM. J Nutr Biochem2023; 116: 109322.
5.
DursunECandasEYilmazerS, et al.Amyloid beta 1-42 alters the expression of miRNAs in cortical neurons. J Mol Neurosci2019; 67: 181–192.
6.
DursunEGezen-AkD. Vitamin D receptor is present on the neuronal plasma membrane and is co-localized with amyloid precursor protein, ADAM10 or Nicastrin. PLoS One2017; 12: e0188605.
7.
DursunEGezen-AkDYilmazerS. The ınfluence of vitamin D treatment on the ınducible nitric oxide synthase (INOS) expression in primary hippocampal neurons. Noro Psikiyatr Ars2014; 51: 163–168.
8.
Gezen-AkDYurttasZCamogluT, et al.Could amyloid-beta 1-42 or alpha-synuclein ınteract directly with mitochondrial DNA? A hypothesis. ACS Chem Neurosci2022; 13: 2803–2812.
9.
Gezen-AkDAtasoyILCandasE, et al.The transcriptional regulatory properties of amyloid beta 1-42 may ınclude regulation of genes related to neurodegeneration. Neuromolecular Med2018; 20: 363–375.
10.
Gezen-AkDAtasoyILCandasE, et al.Vitamin D receptor regulates amyloid beta 1-42 production with protein disulfide ısomerase A3. ACS Chem Neurosci2017; 8: 2335–2346.
11.
HonigLSVellasBWoodwardM, et al.Trial of solanezumab for mild dementia due to Alzheimer's disease. N Engl J Med2018; 378: 321–330.
12.
OlssonBLautnerRAndreassonU, et al.CSF And blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol2016; 15: 673–684.
13.
ChaplotKJarvelaTSLindbergI. Secreted chaperones in neurodegeneration. Front Aging Neurosci2020; 12: 268.
14.
BlennowKZetterbergH. Biomarkers for Alzheimer's disease: current status and prospects for the future. J Intern Med2018; 284: 643–663.
15.
MacarioAJConway de MacarioE. Chaperonopathies and chaperonotherapy. FEBS Lett2007; 581: 3681–3688.
16.
Tiroli-CepedaAORamosCH. An overview of the role of molecular chaperones in protein homeostasis. Protein Pept Lett2011; 18: 101–109.
17.
MaitiPMannaJVeleriS, et al.Molecular chaperone dysfunction in neurodegenerative diseases and effects of curcumin. Biomed Res Int2014; 2014: 495091.
18.
TurturiciGSconzoGGeraciF. Hsp70 and its molecular role in nervous system diseases. Biochem Res Int2011; 2011: 618127.
19.
VilasiSBuloneDCaruso BavisottoC, et al.Chaperonin of group I: oligomeric spectrum and biochemical and biological ımplications. Front Mol Biosci2018; 4: 99.
20.
CampanellaCD'AnneoAMarino GammazzaA, et al.The histone deacetylase inhibitor SAHA induces HSP60 nitration and its extracellular release by exosomal vesicles in human lung-derived carcinoma cells. Oncotarget2016; 7: 28849–28867.
21.
Caruso BavisottoCNikolicDMarino GammazzaA, et al.The dissociation of the Hsp60/pro-Caspase-3 complex by bis(pyridyl)oxadiazole copper complex (CubipyOXA) leads to cell death in NCI-H292 cancer cells. J Inorg Biochem2017; 170: 8–16.
22.
PaulSMahantaS. Association of heat-shock proteins in various neurodegenerative disorders: is it a master key to open the therapeutic door?Mol Cell Biochem2014; 386: 45–61.
23.
WilhelmusMMde WaalRMVerbeekMM. Heat shock proteins and amateur chaperones in amyloid-Beta accumulation and clearance in Alzheimer's disease. Mol Neurobiol2007; 35: 203–216.
24.
MaoYFisherDWYangS, et al.Protein-protein interactions underlying the behavioral and psychological symptoms of dementia (BPSD) and Alzheimer's disease. PLoS One2020; 15: e0226021.
25.
MohamedBABarakatAZZimmermannWH, et al.Targeted disruption of Hspa4 gene leads to cardiac hypertrophy and fibrosis. J Mol Cell Cardiol2012; 53: 459–468.
26.
LeeMYChoiYSChoiJS, et al.An immunohistochemical study of APG-2 protein in the rat hippocampus after transient forebrain ischemia. Brain Res2002; 924: 237–241.
27.
GorantlaNVChinnathambiS. Tau protein squired by molecular chaperones during Alzheimer's disease. J Mol Neurosci2018; 66: 356–368.
28.
Al-RamahiILamYCChenHK, et al.CHIP Protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradation. J Biol Chem2006; 281: 26714–26724.
29.
KotlyarMPastrelloCPivettaF, et al.In silico prediction of physical protein interactions and characterization of interactome orphans. Nat Methods2015; 12: 79–84.
30.
McKhannGMKnopmanDSChertkowH, et al.The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 263–269.
31.
PrzyklenkBBauernfeindAHorlG, et al.Serologic response to Candida albicans and Aspergillus fumigatus in cystic fibrosis. Infection1987; 15: 308–310.
32.
AlbertMSDeKoskySTDicksonD, et al.The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 270–279.
33.
AlayliogluMGezen-AkDDursunE, et al.The association between clusterin and APOE polymorphisms and late-onset Alzheimer disease in a Turkish cohort. J Geriatr Psychiatry Neurol2016; 29: 221–226.
34.
DurlakJA. How to select, calculate, and interpret effect sizes. J Pediatr Psychol2009; 34: 917–928.
35.
Marino GammazzaARestivoVBaschiR, et al.Circulating molecular chaperones in subjects with amnestic mild cognitive ımpairment and Alzheimer's disease: data from the Zabut Aging Project. J Alzheimers Dis2022; 87: 161–172.
36.
Gezen-AkDDursunEHanagasiH, et al.BDNF, TNFalpha, HSP90, CFH, and IL-10 serum levels in patients with early or late onset Alzheimer's disease or mild cognitive impairment. J Alzheimers Dis2013; 37: 185–195.
WeiHZhangYJiaY, et al.Heat shock protein 90: biological functions, diseases, and therapeutic targets. MedComm (2020)2024; 5: e470.
39.
SaharaNMurayamaMMizorokiT, et al.In vivo evidence of CHIP up-regulation attenuating tau aggregation. J Neurochem2005; 94: 1254–1263.
40.
SulistioYAHeeseK. The ubiquitin-proteasome system and molecular chaperone deregulation in Alzheimer's disease. Mol Neurobiol2016; 53: 905–931.
41.
PetrucelliLDicksonDKehoeK, et al.CHIP And Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet2004; 13: 703–714.
42.
PrattWBGestwickiJEOsawaY, et al.Targeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases. Annu Rev Pharmacol Toxicol2015; 55: 353–371.
43.
KumarPAmbastaRKVeereshwarayyaV, et al.CHIP And HSPs interact with beta-APP in a proteasome-dependent manner and influence Abeta metabolism. Hum Mol Genet2007; 16: 848–864.
44.
SinghAKPatiU. CHIP Stabilizes amyloid precursor protein via proteasomal degradation and p53-mediated trans-repression of beta-secretase. Aging Cell2015; 14: 595–604.
45.
MoraweTHiebelCKernA, et al.Protein homeostasis, aging and Alzheimer's disease. Mol Neurobiol2012; 46: 41–54.
46.
GenisDOrtega-CuberoSSan NicolasH, et al.Heterozygous STUB1 mutation causes familial ataxia with cognitive affective syndrome (SCA48). Neurology2018; 91: e1988–e1998.
ShiYWangJLiJD, et al.Identification of CHIP as a novel causative gene for autosomal recessive cerebellar ataxia. PLoS One2013; 8: e81884.
49.
De MicheleGLietoMGalatoloD, et al.Spinocerebellar ataxia 48 presenting with ataxia associated with cognitive, psychiatric, and extrapyramidal features: a report of two Italian families. Parkinsonism Relat Disord2019; 65: 91–96.
50.
PalvadeauRKaya-GulecZESimsirG, et al.Cerebellar cognitive-affective syndrome preceding ataxia associated with complex extrapyramidal features in a Turkish SCA48 family. Neurogenetics2020; 21: 51–58.
51.
PakdamanYBerlandSBustadHJ, et al.Genetic dominant variants in STUB1, segregating in families with SCA48, display ın vitro functional ımpairments ındistinctive from recessive variants associated with SCAR16. Int J Mol Sci2021; 22: 5870.
52.
RavelJMBenkiraneMCalmelsN, et al.Expanding the clinical spectrum of STIP1 homology and U-box containing protein 1-associated ataxia. J Neurol2021; 268: 1927–1937.
53.
ReisMCPatrunJAcklN, et al.A severe dementia syndrome caused by ıntron retention and cryptic splice site activation in STUB1 and exacerbated by TBP repeat expansions. Front Mol Neurosci2022; 15: 878236.
54.
BohushABieganowskiPFilipekA. Hsp90 and ıts co-chaperones in neurodegenerative diseases. Int J Mol Sci2019; 20: 4976.
55.
JoshiVAmanullahAUpadhyayA, et al.A decade of boon or burden: what has the CHIP ever done for cellular protein quality control mechanism ımplicated in neurodegeneration and aging?Front Mol Neurosci2016; 9: 93.
56.
BertramLLillCMTanziRE. The genetics of Alzheimer disease: back to the future. Neuron2010; 68: 270–281.
57.
SlotRERKesterMIVan HartenAC, et al.Apoe and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF Abeta42, levels in non-demented elderly. Neurobiol Aging2019; 79: 101–109.
58.
DursunEAlayliogluMBilgicB, et al.Vitamin D deficiency might pose a greater risk for ApoEvarepsilon4 non-carrier Alzheimer's disease patients. Neurol Sci2016; 37: 1633–1643.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
